- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03104283
Apatinib for the Elderly Advanced Gastric Cancer
A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC)
Studieöversikt
Detaljerad beskrivning
The trial is funded by Chinese Society of Clinical Oncology-Beijing Xisike Clinical Oncology Research Fundation. The trial is prepared to be registered on the clinicaltrail.gov.
Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participate in all steps of the trail, including the record of the data, which is compared by the investigators. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the staff of research and financial department of Affliated Hospital of Qinghai University.
Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.
Source data verification: The investigators assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.
Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant.
Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.
Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 47 participants to take part in the trail. The investigators can recruit about 20 participants every year according to previous experiences, so the investigators should recruit about two years.
Plan for missing data: The investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results.
Statistical analysis plan: Statistical analyses would be performed by using SPSS software, version 13.0 (SPSS Inc., IL, USA). Survival analysis would be performed using Kaplan-Meier methodology. Fisher's exact test would be used to analyze the efficacy of treatment. Cox proportional hazards model would be used for multivariate analysis. The level of significance is defined as P < 0.05.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Qinghai
-
Xining, Qinghai, Kina, 810000
- Affiliated Hospital of Qinghai University
-
Xining, Qinghai, Kina, 810000
- People's Hospital of Qinghai Province
-
Xining, Qinghai, Kina, 810000
- Qinghai Red Cross Hospital
-
Xining, Qinghai, Kina, 810000
- The Fifth People's Hospital of Qinghai Province
-
-
Shanxi
-
Yangquan, Shanxi, Kina, 045000
- Yangquan No.1 People's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Elderly patients (aged ≥ 60 years) with histologically confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
- Progression with or intolerance to one or more lines of chemotherapy;
- At least one measurable lesion as defined by RECIST 1.1;
- With acceptable hematologic, cardiac, hepatic, pulmonary and renal function;
- Can take apatinib orally;
- Estimated life expectancy ≥ 3 months.
Exclusion Criteria:
- Patients cannot take apatinib orally for any reason;
- Patients with uncontrolled central nervous system (CNS) metastases;
- Patients with massive hydrothorax or ascites;
- Proteinuria 2+ or 24-hour urinary protein ≥ 1g;
- Newly-happened traumatism or pathological fracture;
- Estimated life expectancy ˂ 3 months;
- Received chemotherapy in the past 28 days before enrollment;
- Patients with uncontrolled blood pressure on medication (≥ 140/90 mmHg);
- Patients with bleeding tendency, receiving thrombolytics or anticoagulants, receiving intravenous antibiotic treatment, had received bevacizumab or other VEGF TKIs before, or with other primary malignancy (except basal cell skin cancer or cervical carcinoma in situ).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Apatinib Group
take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
|
take apatinib orally until disease progression or appearance of unbearable toxicity
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-free survival (PFS)
Tidsram: 1 year
|
PFS was defined to be the time from registration to the date of disease progress sion or death resulting from any cause.
|
1 year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective response rate (ORR)
Tidsram: 1 year
|
ORR was defined as the proportion of eligible patients who achieved a confirmed complete response(CR )or partial response (PR) by RECIST 1.1 criteria evaluated by the investigators.
|
1 year
|
|
Disease control rate (DCR)
Tidsram: 1 year
|
DCR was defined as the proportion of patients who achieved CR, PR and stable disease (SD) for at least 8 weeks.
|
1 year
|
|
Overall survival (OS)
Tidsram: 1 year
|
OS was defined to be the time from registration to the date of death resulting from any cause or the last follow-up visit.
|
1 year
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Gastrointestinala sjukdomar
- Magsjukdomar
- Neoplasmer i magen
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Proteinkinashämmare
- Apatinib
Andra studie-ID-nummer
- AHQU-2017001
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Magcancer
-
Qilu Hospital of Shandong UniversityRekryteringGastric Cardia CancerKina
-
Universitätsklinikum Hamburg-EppendorfCentre Hospitalier Universitaire de Nice; Olympus Corporation; Keio University och andra samarbetspartnersAvslutadGastric Focal LesionFrankrike
-
Cairo UniversityRekrytering
-
RSP Systems A/SAvslutad
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AvslutadRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertikal sleeve gastrectomy | Magbandning | Bypass, GastricFörenta staterna
-
Cantonal Hospital of St. GallenAvslutadBariatrisk kirurgi (gastric bypass)Schweiz
-
State University of New York - Upstate Medical...AvslutadGastric Bypass StatusFörenta staterna
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)IndragenGastric Bypass-kirurgi
-
Medtronic - MITGAvslutad
-
Instituto Ecuatoriano de Enfermedades DigestivasAvslutad
Kliniska prövningar på Apatinib
-
Song PengHar inte rekryterat ännuHepatocellulärt karcinom Ej resektabeltKina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Har inte rekryterat ännu
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Har inte rekryterat ännuHepatocellulärt karcinom (HCC) | Inoperabelt hepatocellulärt karcinom (HCC) | Levercancer VuxenKina
-
Linhui PengRekryteringHepatocellulärt karcinom (HCC) | Kemoterapi effektKina
-
Beijing Friendship HospitalRekryteringAdenocarcinom i magen | Adenocarcinom av GE Junction | AdebrelimabKina
-
The First Affiliated Hospital of Zhengzhou UniversityRekryteringAvancerad magcancer | SHR1701Kina
-
First Affiliated Hospital of Chongqing Medical...Har inte rekryterat ännuImmunmodulering | Hepatocellulära karcinom | Resistens mot immunterapi | LäkemedelsåteranvändningKina
-
Fujian Medical UniversityHar inte rekryterat ännu
-
Guangzhou Virotech Pharmaceutical Co., Ltd.Rekrytering
-
Elevar TherapeuticsAvslutadAdenoid cystiskt karcinomFörenta staterna, Korea, Republiken av